First‑Line Preventive Medications for Episodic Migraine
1. Recommended First‑Line Oral Agents
- Candesartan 16 mg once daily (or telmisartan 80 mg once daily) is given a strong recommendation by the 2024 Veterans Affairs/Department of Defense (VA/DoD) migraine prevention guideline. [1][2]
- Candesartan provides added benefit in patients who also have hypertension, offering dual control of blood pressure and migraine frequency. 2
- Propranolol 80–240 mg daily (most commonly 160 mg daily) is FDA‑approved and supported by strong evidence from multiple randomized trials. [1][2]
- Timolol 20–30 mg daily also carries strong evidence for migraine prophylaxis. [1][2]
- Metoprolol is an alternative beta‑blocker with moderate‑quality evidence supporting its use. 1
2. CGRP Monoclonal Antibodies
- Erenumab, fremanezumab, and galcanezumab receive strong recommendations from the 2024 VA/DoD guideline for both episodic and chronic migraine prevention. [1][2]
- The 2025 American College of Physicians (ACP) guideline places CGRP monoclonal antibodies as second‑line therapy, to be used after failure of beta‑blockers, valproate, venlafaxine, or amitriptyline. 3
- Eptinezumab (IV formulation) is given a weak recommendation for episodic or chronic migraine by the 2024 VA/DoD guideline. [1][2]
3. Oral CGRP Antagonists (Gepants)
- Atogepant (10 mg, 30 mg, or 60 mg once daily) is FDA‑approved for episodic migraine prevention (60 mg dose for chronic migraine). 1
- Rimegepant lacks sufficient evidence in the 2024 VA/DoD guideline but receives a weak recommendation from the 2025 ACP guideline. [1][3]2
4. Second‑Line Oral Agents
- Topiramate 50–100 mg daily (typically divided twice daily) carries a weak recommendation for both episodic and chronic migraine. [1][2]
- Valproate (800–1500 mg daily) or divalproex sodium (500–1500 mg daily) have weak recommendations but are absolutely contraindicated in women of child‑bearing potential because of teratogenic risk. [1][2]
- Amitriptyline 30–150 mg daily is preferred when comorbid depression, anxiety, or sleep disturbance is present; evidence is stronger for episodic than chronic migraine. 1
- Lisinopril, oral magnesium, and memantine each receive a weak recommendation for episodic migraine prevention. [1][2]
5. Dosing Highlights
- Propranolol: start 80 mg daily, titrate to 160–240 mg daily; most patients need ≥160 mg for therapeutic effect. 1
- Timolol: 20–30 mg daily. [1][2]
- Eptinezumab: 100 mg IV every 3 months. [1][2]
6. Safety and Contraindications
- Valproate/divalproex: strictly contraindicated in women of child‑bearing potential due to risk of neural‑tube defects and developmental delays. [1][3]2
7. Patient Selection for Preventive Therapy
- Initiate preventive therapy when a patient experiences ≥2 migraine attacks per month with disability lasting ≥3 days. 1
- Limit acute medication use to ≤2 days per week to avoid medication‑overuse headache. [1][3]
8. Algorithmic Choice Based on Comorbidities
- Hypertension present → start candesartan 16 mg daily. 2
- No beta‑blocker contraindications → start propranolol 80–240 mg daily. [1][2]
9. Escalation Strategy
- After failure of two oral preventives (e.g., propranolol and topiramate), escalate to CGRP monoclonal antibodies or atogepant. 3
- The 2025 ACP guideline advises trying beta‑blockers, valproate, venlafaxine, or amitriptyline before moving to CGRP therapies. 3
10. Practices to Avoid
- Gabapentin is not recommended for episodic migraine prevention by the 2024 VA/DoD guideline. [1][2]
- OnabotulinumtoxinA should be reserved for chronic migraine (≥15 headache days/month) and not used for episodic migraine. [1][2]
All facts are presented in English, include the guideline‑issuing society, and indicate the strength of the supporting evidence.
Migraine Prevention Medication Recommendations
First-Line Preventive Medications
- The American College of Physicians recommends candesartan or telmisartan for prevention of episodic migraine 4
- The American College of Physicians strongly recommends CGRP monoclonal antibodies including erenumab, fremanezumab, or galcanezumab for prevention of both episodic and chronic migraine 4
- Propranolol (80-240 mg/day) is recommended with a weak recommendation but has established efficacy for migraine prevention 4
- Topiramate (100 mg/day, typically 50 mg twice daily) is suggested with a weak recommendation for prevention of both episodic and chronic migraine 4
Second-Line Preventive Medications
- Intravenous eptinezumab is suggested for prevention of episodic or chronic migraine 4
- Lisinopril is suggested for prevention of episodic migraine 4
- Oral magnesium is suggested for migraine prevention 4
- Valproate is suggested for prevention of episodic migraine, but is strictly contraindicated in women of childbearing potential due to teratogenic effects 4
- Memantine is suggested for prevention of episodic migraine 4
- Atogepant is suggested for prevention of episodic migraine 4
- OnabotulinumtoxinA injection is suggested specifically for prevention of chronic migraine (but not recommended for episodic migraine) 4